Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I Ruben A. Mesa, Srdan Verstovsek,

Slides:

Advertisements

Similar presentations

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.

Advertisements

Effect of fish oil supplementation on serum triglycerides, LDL cholesterol and LDL subfractions in hypertriglyceridemic adults B. Oelrich, A. Dewell,

Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled.

Volume 26, Issue 2, Pages e2 (August 2017)

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride.

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

Julian A. Abrams, MD, MS, Sri Komanduri, MD, Nicholas J

Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management Jorge E. Cortes, Carlos.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera.

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower- Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005.

Circulating MicroRNAs as Biomarkers of Colorectal Cancer: Results From a Genome- Wide Profiling and Validation Study María Dolores Giráldez, Juan José.

Volume 148, Issue 4, Pages e8 (April 2015)

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data Kathleen Lang,

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient.

Vikas Gupta, Jason Gotlib, Jerald P. Radich, Nicolaus M

Prognostic Nomogram for Overall Survival in Extranodal Natural Killer/T-Cell Lymphoma Patients Kaiguo Li, Ruyue Wang, Shiting Huang, Xinbin Pan, Hongmin.

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics Vincent T. Ma, Philip S. Boonstra,

Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission Quoc Truong,

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.

James H. O'Keefe, M.D., Carl J. Lavie, M.D., Ben D. McCallister, M.D.

Meredith Kilgore, PhD, Paul Muntner, PhD, J

Carmelo V. Venero, MD, Paul D. Thompson, MD, Antonio B. Fernandez, MD

Subepithelial Corneal Immunoglobulin Deposition as a Manifestation of Multiple Myeloma: A Case Report and Literature Review Trent P. Wang, Steven G.

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo,

Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France Nicolas Despiégel, Chantal Touboul, Alain.

Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study Rena Buckstein,

Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment.

Volume 155, Issue 5, Pages e6 (November 2018)

Genetic Mutations in B-Acute Lymphoblastic Leukemia Among African American and European American Children Amit Reddy, Ingrid Espinoza, Dana Cole, Jason.

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma John M. Burke,

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma

Volume 62, Issue 1, Pages (July 2002)

ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies

Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera.

Recommendations for the management of patients with homozygous familial hypercholesterolaemia: Overview of a new European Atherosclerosis Society consensus.

Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data Preetesh Jain, Hagop Kantarjian,

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa,

Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides Francine Foss, Madeleine Duvic, Adam Lerner, Joel Waksman, Sean Whittaker

Volume 26, Issue 2, Pages e2 (August 2017)

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic.

Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single- Institution Experience Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola,

Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice Abdalla Awidi, Salah Abbasi,

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review Jill A. Bell, Aaron.

Elevated High-Density Lipoprotein Cholesterol Is Associated with Hyponatremia in Hypertensive Patients Ariel Israel, MD, PhD, Ehud Grossman, MD The.

Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)

Rhanderson Cardoso, MD, Roger S

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Volume 67, Issue 4, Pages (April 2005)

Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study Jorge E.

Pure Erythroid Leukemia Presenting in a HIV-Positive Patient

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.

Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1,

Urbanization, mainly rurality, but not altitude is associated with dyslipidemia profiles Maria Lazo-Porras, Antonio Bernabe-Ortiz, Renato Quispe, German.

III. Treating dyslipidemias

Autologous Stem Cell Transplantation for POEMS Syndrome

Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

Presentation transcript:

Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I Ruben A. Mesa, Srdan Verstovsek, Vikas Gupta, John O. Mascarenhas, Ehab Atallah, Timothy Burn, William Sun, Victor Sandor, Jason Gotlib Clinical Lymphoma, Myeloma and Leukemia Volume 15, Issue 4, Pages 214-221.e1 (April 2015) DOI: 10.1016/j.clml.2014.12.008 Copyright © 2015 The Authors Terms and Conditions

Figure 1 Mean Change in (A) Body Weight, (B) Total Cholesterol, and (C) Albumin Over Time in Patients Who Received Ruxolitinib or Placebo. Vertical Lines Indicate the Standard Error of the Mean Clinical Lymphoma, Myeloma and Leukemia 2015 15, 214-221.e1DOI: (10.1016/j.clml.2014.12.008) Copyright © 2015 The Authors Terms and Conditions

Figure 2 Mean Percentage Change From Baseline in Body Weight in Ruxolitinib-Treated Patients by Week 24 Spleen Volume Reduction Group. Vertical Lines Indicate the Standard Error of the Mean Clinical Lymphoma, Myeloma and Leukemia 2015 15, 214-221.e1DOI: (10.1016/j.clml.2014.12.008) Copyright © 2015 The Authors Terms and Conditions

Figure 3 Mean Percentage Change From Baseline in Body Weight in Ruxolitinib-Treated Patients by Week 24 Total Symptom Score Reduction Group. Vertical Lines Indicate the Standard Error of the Mean Clinical Lymphoma, Myeloma and Leukemia 2015 15, 214-221.e1DOI: (10.1016/j.clml.2014.12.008) Copyright © 2015 The Authors Terms and Conditions

Figure 4 Hierarchical Clustering of Plasma Markers With Changes in Weight Alone (Top), Changes in Total Cholesterol Alone (Middle), or Changes in Albumin Alone (Bottom). Red Denotes Increases at Week 24 Relative to Baseline. Green Denotes Decreases at Week 24 Relative to Baseline. Because of Differences in the Magnitude of Changes Between Markers, the Heat Map Color Intensities Were Normalized Clinical Lymphoma, Myeloma and Leukemia 2015 15, 214-221.e1DOI: (10.1016/j.clml.2014.12.008) Copyright © 2015 The Authors Terms and Conditions

Supplemental Figure 1 Box and Whisker Plots of (A) Total Cholesterol, (B) LDL-C, and (C) HDL-C Levels Over Time in Ruxolitinib-Treated Patients. The Solid Red Line Represents the Median Abbreviations: HDL-C = High-Density Lipoprotein Cholesterol; LDL-C = Low-Density Lipoprotein Cholesterol. Clinical Lymphoma, Myeloma and Leukemia 2015 15, 214-221.e1DOI: (10.1016/j.clml.2014.12.008) Copyright © 2015 The Authors Terms and Conditions